Skip to main content

Advertisement

SpringerLink
Log in

EGFR mutations and the terminal respiratory unit

  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Abstract

Considerable knowledge has accumulated about mutations of the epidermal growth factor receptor (EGFR)-tyrosine kinase domain since these were first identified in 2004. Patients with nonsmall cell lung cancer with this mutation show dramatic clinical responses to treatment with EGFR-tyrosine kinase inhibitors, whose effectiveness has been established recently in large clinical trials. Most of the mechanisms responsible for resistance to treatment, which most responders experience eventually, have been elucidated, and methods to overcome resistance have been developed. In addition to the clinical benefit, understanding EGFR mutations sheds new light on the molecular and pathological aspects of this adenocarcinoma subset, which include frequent development in nonsmokers or females, and particular clusters within the molecular classification in lung cancer. In contrast to the involvement of EGFR mutations in the early stage of lung adenocarcinoma development, EGFR amplification is superimposed on the progression to invasive cancer. In this review, I summarize the clinicopathological characteristics of EGFR mutations in lung cancer. I also provide an overview of the current understanding of the lung adenocarcinoma subset harboring EGFR mutations with special reference to the molecular classification of lung cancer and the novel concept of the “terminal respiratory unit.”

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Hirsch, F. R., Scagliotti, G. V., Langer, C. J., Varella-Garcia, M., & Franklin, W. A. (2003). Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. Lung Cancer, 41(Suppl 1), S29–S42.

    PubMed  Google Scholar 

  2. Thienelt, C. D., Bunn, P. A., Jr., Hanna, N., Rosenberg, A., Needle, M. N., Long, M. E., et al. (2005). Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. Journal of Clinical Oncology, 23, 8786–8793.

    PubMed  Google Scholar 

  3. Kim, E., Mauer, A., Fossella, F., Jamison, T. A., Kies, M. S., Pisters, K. M., et al. (2002). A phase II study of Erbitux (IMC-C225), an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer (NSCLC). Proceedings of the American Society Clinical Oncology, 21, (abstr 1168) 293.

    Google Scholar 

  4. Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J. Y., et al. (2003). Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology, 21, 2237–2246.

    PubMed  CAS  Google Scholar 

  5. Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, T. J., Jr., Prager, D., Belani, C. P., et al. (2003). Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. Jama, 290, 2149–2158.

    PubMed  CAS  Google Scholar 

  6. Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New England Journal of Medicine, 350, 2129–2139.

    PubMed  CAS  Google Scholar 

  7. Paez, J. G., Janne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., et al. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 304, 1497–1500.

    PubMed  CAS  Google Scholar 

  8. Minna, J. D., Gazdar, A. F., Sprang, S. R., & Herz, J. (2004). Cancer. A bull’s eye for targeted lung cancer therapy. Science, 304, 1458–1461.

    PubMed  CAS  Google Scholar 

  9. Weinstein, I. B. (2002). Cancer. Addiction to oncogenes—the Achilles heal of cancer. Science, 297, 63–64.

    PubMed  CAS  Google Scholar 

  10. Shigematsu, H., & Gazdar, A. F. (2006). Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. International Journal of Cancer, 118, 257–262.

    CAS  Google Scholar 

  11. Mitsudomi, T., & Yatabe, Y. (2007). Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Science, 98, 1817–1824.

    PubMed  CAS  Google Scholar 

  12. Greulich, H., Chen, T. H., Feng, W., Janne, P. A., Alvarez, J. V., Zappaterra, M., et al. (2005). Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med, 2, e313.

    PubMed  Google Scholar 

  13. Riely, G. J., Pao, W., Pham, D., Li, A. R., Rizvi, N., Venkatraman, E. S., et al. (2006). Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clinical Cancer Research, 12, 839–844.

    PubMed  CAS  Google Scholar 

  14. Jackman, D. M., Yeap, B. Y., Sequist, L. V., Lindeman, N., Holmes, A. J., Joshi, V. A., et al. (2006). Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clinical Cancer Research, 12, 3908–3914.

    PubMed  CAS  Google Scholar 

  15. Mitsudomi, T., Kosaka, T., Endoh, H., Horio, Y., Hida, T., Mori, S., et al. (2005). Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. Journal of Clinical Oncology, 23, 2513–2520.

    PubMed  CAS  Google Scholar 

  16. Yatabe, Y., & Mitsudomi, T. (2007). Epidermal growth factor receptor mutations in lung cancers. Pathology International, 57, 233–244.

    PubMed  CAS  Google Scholar 

  17. Marchetti, A., Felicioni, L., & Buttitta, F. (2006). Assessing EGFR mutations. New England Journal of Medicine, 354, 526–528. author reply -8.

    PubMed  CAS  Google Scholar 

  18. Thatcher, N., Chang, A., Parikh, P., Rodrigues Pereira, J., Ciuleanu, T., von Pawel, J., et al. (2005). Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet, 366, 1527–1537.

    PubMed  CAS  Google Scholar 

  19. Han, S. W., Kim, T. Y., Hwang, P. G., Jeong, S., Kim, J., Choi, I. S., et al. (2005). Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. Journal of Clinical Oncology, 23, 2493–2501.

    PubMed  CAS  Google Scholar 

  20. Bezjak, A., Tu, D., Seymour, L., Clark, G., Trajkovic, A., Zukin, M., et al. (2006). Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. Journal of Clinical Oncology, 24, 3831–3837.

    PubMed  CAS  Google Scholar 

  21. Ando, M., Okamoto, I., Yamamoto, N., Takeda, K., Tamura, K., Seto, T., et al. (2006). Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. Journal of Clinical Oncology, 24, 2549–2556.

    PubMed  CAS  Google Scholar 

  22. Ciardiello, F., De Vita, F., Orditura, M., & Tortora, G. (2004). The role of EGFR inhibitors in nonsmall cell lung cancer. Current Opinion in Oncology, 16, 130–135.

    PubMed  CAS  Google Scholar 

  23. Ho, C., Murray, N., Laskin, J., Melosky, B., Anderson, H., & Bebb, G. (2005). Asian ethnicity and adenocarcinoma histology continues to predict response to gefitinib in patients treated for advanced non-small cell carcinoma of the lung in North America. Lung Cancer, 49, 225–231.

    PubMed  Google Scholar 

  24. Tsao, A. S., Tang, X. M., Sabloff, B., Xiao, L., Shigematsu, H., Roth, J., et al. (2006). Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. Journal of Thoracic Oncol, 1, 231–239.

    Google Scholar 

  25. Nomura, M., Shigematsu, H., Li, L., Suzuki, M., Takahashi, T., Estess, P., et al. (2007). Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. PLoS Med, 4, e125.

    PubMed  Google Scholar 

  26. Krishnaswamy, S., Kanteti, R., Duke-Cohan, J. S., Loganathan, S., Liu, W., Ma, P. C., et al. (2009). Ethnic differences and functional analysis of MET mutations in lung cancer. Clinical Cancer Research, 15, 5714–5723.

    PubMed  CAS  Google Scholar 

  27. Nose, N., Sugio, K., Oyama, T., Nozoe, T., Uramoto, H., Iwata, T., et al. (2009). Association between estrogen receptor-beta expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung. Journal of Clinical Oncology, 27, 411–417.

    PubMed  CAS  Google Scholar 

  28. Raso, M. G., Behrens, C., Herynk, M. H., Liu, S., Prudkin, L., Ozburn, N. C., et al. (2009). Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clinical Cancer Research, 15, 5359–5368.

    PubMed  CAS  Google Scholar 

  29. Stabile, L. P., Lyker, J. S., Gubish, C. T., Zhang, W., Grandis, J. R., & Siegfried, J. M. (2005). Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Research, 65, 1459–1470.

    PubMed  CAS  Google Scholar 

  30. Matsuo, K., Ito, H., Yatabe, Y., Hiraki, A., Hirose, K., Wakai, K., et al. (2007). Risk factors differ for non-small-cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case-control study in Japanese. Cancer Science, 98, 96–101.

    PubMed  CAS  Google Scholar 

  31. Kosaka, T., Yatabe, Y., Endoh, H., Kuwano, H., Takahashi, T., & Mitsudomi, T. (2004). Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Research, 64, 8919–8923.

    PubMed  CAS  Google Scholar 

  32. Pham, D., Kris, M. G., Riely, G. J., Sarkaria, I. S., McDonough, T., Chuai, S., et al. (2006). Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. Journal of Clinical Oncology, 24, 1700–1704.

    PubMed  CAS  Google Scholar 

  33. Seike, M., Goto, A., Okano, T., Bowman, E. D., Schetter, A. J., Horikawa, I., et al. (2009). MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proceedings of the National Academy of Sciences of the United States of America, 106, 12085–12090.

    PubMed  CAS  Google Scholar 

  34. Toyooka, S., Matsuo, K., Shigematsu, H., Kosaka, T., Tokumo, M., Yatabe, Y., et al. (2007). The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer. Clinical Cancer Research, 13, 5763–5768.

    PubMed  CAS  Google Scholar 

  35. Tanaka, T., Matsuoka, M., Sutani, A., Gemma, A., Maemondo, M., Inoue, A., et al. (2009). Frequency of and variables associated with the EGFR mutation and its subtypes. Int J Cancer, 126, 651–655.

    Google Scholar 

  36. Kobayashi, S., Boggon, T. J., Dayaram, T., Janne, P. A., Kocher, O., Meyerson, M., et al. (2005). EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. New England Journal of Medicine, 352, 786–792.

    PubMed  CAS  Google Scholar 

  37. Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., et al. (2005). Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med, 2, e73.

    PubMed  Google Scholar 

  38. Kosaka, T., Yatabe, Y., Endoh, H., Yoshida, K., Hida, T., Tsuboi, M., et al. (2006). Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clinical Cancer Research, 12, 5764–5769.

    PubMed  CAS  Google Scholar 

  39. Balak, M. N., Gong, Y., Riely, G. J., Somwar, R., Li, A. R., Zakowski, M. F., et al. (2006). Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clinical Cancer Research, 12, 6494–6501.

    PubMed  CAS  Google Scholar 

  40. Bean, J., Riely, G. J., Balak, M., Marks, J. L., Ladanyi, M., Miller, V. A., et al. (2008). Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clinical Cancer Research, 14, 7519–7525.

    PubMed  CAS  Google Scholar 

  41. Engelman, J. A., Mukohara, T., Zejnullahu, K., Lifshits, E., Borras, A. M., Gale, C. M., et al. (2006). Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. Journal of Clinical Investigation, 116, 2695–2706.

    PubMed  CAS  Google Scholar 

  42. Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., et al. (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science, 316, 1039–1043.

    PubMed  CAS  Google Scholar 

  43. Yano, S., Wang, W., Li, Q., Matsumoto, K., Sakurama, H., Nakamura, T., et al. (2008). Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Research, 68, 9479–9487.

    PubMed  CAS  Google Scholar 

  44. Laurent-Puig, P., Cayre, A., Manceau, G., Buc, E., Bachet, J. B., Lecomte, T., et al. (2009). Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. Journal of Clinical Oncology, 27, 5924–5930.

    PubMed  CAS  Google Scholar 

  45. Loupakis, F., Pollina, L., Stasi, I., Ruzzo, A., Scartozzi, M., Santini, D., et al. (2009). PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. Journal of Clinical Oncology, 27, 2622–2629.

    PubMed  CAS  Google Scholar 

  46. Frattini, M., Saletti, P., Romagnani, E., Martin, V., Molinari, F., Ghisletta, M., et al. (2007). PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. British Journal of Cancer, 97, 1139–1145.

    PubMed  CAS  Google Scholar 

  47. Sos, M. L., Koker, M., Weir, B. A., Heynck, S., Rabinovsky, R., Zander, T., et al. (2009). PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Research, 69, 3256–3261.

    PubMed  CAS  Google Scholar 

  48. Marchetti, A., Milella, M., Felicioni, L., Cappuzzo, F., Irtelli, L., Del Grammastro, M., et al. (2009). Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. Neoplasia, 11, 1084–1092.

    PubMed  CAS  Google Scholar 

  49. Coe, B. P., Lockwood, W. W., Girard, L., Chari, R., Macaulay, C., Lam, S., et al. (2006). Differential disruption of cell cycle pathways in small cell and non-small cell lung cancer. British Journal of Cancer, 94, 1927–1935.

    PubMed  CAS  Google Scholar 

  50. Cerny, T., Barnes, D. M., Hasleton, P., Barber, P. V., Healy, K., Gullick, W., et al. (1986). Expression of epidermal growth factor receptor (EGF-R) in human lung tumours. British Journal of Cancer, 54, 265–269.

    PubMed  CAS  Google Scholar 

  51. Sobol, R. E., Astarita, R. W., Hofeditz, C., Masui, H., Fairshter, R., Royston, I., et al. (1987). Epidermal growth factor receptor expression in human lung carcinomas defined by a monoclonal antibody. Journal of the National Cancer Institute, 79, 403–407.

    PubMed  CAS  Google Scholar 

  52. Tatematsu, A., Shimizu, J., Murakami, Y., Horio, Y., Nakamura, S., Hida, T., et al. (2008). Epidermal growth factor receptor mutations in small cell lung cancer. Clinical Cancer Research, 14, 6092–6096.

    PubMed  CAS  Google Scholar 

  53. Zakowski, M. F., Ladanyi, M., & Kris, M. G. (2006). EGFR mutations in small-cell lung cancers in patients who have never smoked. New England Journal of Medicine, 355, 213–215.

    PubMed  CAS  Google Scholar 

  54. Okamoto, I., Araki, J., Suto, R., Shimada, M., Nakagawa, K., & Fukuoka, M. (2006). EGFR mutation in gefitinib-responsive small-cell lung cancer. Annals of Oncology, 17, 1028–1029.

    PubMed  CAS  Google Scholar 

  55. Bell, D. W., Gore, I., Okimoto, R. A., Godin-Heymann, N., Sordella, R., Mulloy, R., et al. (2005). Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nature Genetics, 37, 1315–1316.

    PubMed  CAS  Google Scholar 

  56. Ikeda, K., Nomori, H., Mori, T., Sasaki, J., & Kobayashi, T. (2008). Novel germline mutation: EGFR V843I in patient with multiple lung adenocarcinomas and family members with lung cancer. Annals of Thoracic Surgery, 85, 1430–1432.

    PubMed  Google Scholar 

  57. Pallis, A. G., Voutsina, A., Kalikaki, A., Souglakos, J., Briasoulis, E., Murray, S., et al. (2007). ‘Classical’ but not ‘other’ mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer. British Journal of Cancer, 97, 1560–1566.

    PubMed  CAS  Google Scholar 

  58. Marks, J. L., Golas, B., Kirchoff, T., Miller, V. A., Riely, G. J., Offit, K., et al. (2008). EGFR mutant lung adenocarcinomas in patients with germline BRCA mutations. Journal of Thoracic Oncology, 3, 805.

    PubMed  Google Scholar 

  59. Schwentner, I., Witsch-Baumgartner, M., Sprinzl, G. M., Krugmann, J., Tzankov, A., Jank, S., et al. (2008). Identification of the rare EGFR mutation p.G796S as somatic and germline mutation in white patients with squamous cell carcinoma of the head and neck. Head and Neck, 30, 1040–1044.

    PubMed  Google Scholar 

  60. Cappuzzo, F., Hirsch, F. R., Rossi, E., Bartolini, S., Ceresoli, G. L., Bemis, L., et al. (2005). Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. Journal of the National Cancer Institute, 97, 643–655.

    Article  PubMed  CAS  Google Scholar 

  61. Hirsch, F. R., Varella-Garcia, M., McCoy, J., West, H., Xavier, A. C., Gumerlock, P., et al. (2005). Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. Journal of Clinical Oncology, 23, 6838–6845.

    PubMed  CAS  Google Scholar 

  62. Tsao, M. S., Sakurada, A., Cutz, J. C., Zhu, C. Q., Kamel-Reid, S., Squire, J., et al. (2005). Erlotinib in lung cancer—molecular and clinical predictors of outcome. New England Journal of Medicine, 353, 133–144.

    PubMed  CAS  Google Scholar 

  63. Gandhi, J., Zhang, J., Xie, Y., Soh, J., Shigematsu, H., Zhang, W., et al. (2009). Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS ONE, 4, e4576.

    PubMed  Google Scholar 

  64. Soh, J., Okumura, N., Lockwood, W. W., Yamamoto, H., Shigematsu, H., Zhang, W., et al. (2009). Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. PLoS ONE, 4, e7464.

    PubMed  Google Scholar 

  65. Modrek, B., Ge, L., Pandita, A., Lin, E., Mohan, S., Yue, P., et al. (2009). Oncogenic activating mutations are associated with local copy gain. Molecular Cancer Research, 7, 1244–1252.

    PubMed  CAS  Google Scholar 

  66. Schmidt, L., Duh, F. M., Chen, F., Kishida, T., Glenn, G., Choyke, P., et al. (1997). Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nature Genetics, 16, 68–73.

    PubMed  CAS  Google Scholar 

  67. Bass, A. J., Watanabe, H., Mermel, C. H., Yu, S., Perner, S., Verhaak, R. G., et al. (2009). SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nature Genetics, 41, 1238–1242.

    PubMed  CAS  Google Scholar 

  68. Shimosato, Y., Noguchi, M., & Matsuno, Y. (1993). Adenocarcinoma of the lung: its development and malignant progression. Lung Cancer, 9, 99–108.

    Google Scholar 

  69. Wistuba, I. I., & Gazdar, A. F. (2006). Lung cancer preneoplasia. Annual Review of Pathology, 1, 331–348.

    PubMed  CAS  Google Scholar 

  70. Yatabe, Y., Kosaka, T., Takahashi, T., & Mitsudomi, T. (2005). EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. American Journal of Surgical Pathology, 29, 633–639.

    PubMed  Google Scholar 

  71. Yatabe, Y., Takahashi, T., & Mitsudomi, T. (2008). Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer. Cancer Research, 68, 2106–2111.

    PubMed  CAS  Google Scholar 

  72. Soh, J., Toyooka, S., Ichihara, S., Asano, H., Kobayashi, N., Suehisa, H., et al. (2008). Sequential molecular changes during multistage pathogenesis of small peripheral adenocarcinomas of the lung. Journal of Thoracic Oncology, 3, 340–347.

    PubMed  Google Scholar 

  73. Tang, X., Varella-Garcia, M., Xavier, A. C., Massarelli, E., Ozburn, N., Moran, C., et al. (2008). Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas. Cancer Prevention Research (Philadelphia, PA), 1, 192–200.

    CAS  Google Scholar 

  74. Sholl, L. M., Yeap, B. Y., Iafrate, A. J., Holmes-Tisch, A. J., Chou, Y. P., Wu, M. T., et al. (2009). Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers. Cancer Research, 69, 8341–8348.

    PubMed  CAS  Google Scholar 

  75. Gazdar, A. F., & Minna, J. D. (2008). Deregulated EGFR signaling during lung cancer progression: mutations, amplicons, and autocrine loops. Cancer Prevention Research (Philadelphia, Pa.), 1, 156–60.

    CAS  Google Scholar 

  76. Abbott, J. J., Erickson-Johnson, M., Wang, X., Nascimento, A. G., & Oliveira, A. M. (2006). Gains of COL1A1-PDGFB genomic copies occur in fibrosarcomatous transformation of dermatofibrosarcoma protuberans. Modern Pathology, 19, 1512–1518.

    PubMed  CAS  Google Scholar 

  77. Li, Z. H., Zheng, J., Weiss, L. M., & Shibata, D. (1994). c-k-ras and p53 mutations occur very early in adenocarcinoma of the lung. American Journal of Pathology, 144, 303–309.

    PubMed  CAS  Google Scholar 

  78. Taniguchi, K., Okami, J., Kodama, K., Higashiyama, M., & Kato, K. (2008). Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Science, 99, 929–935.

    PubMed  CAS  Google Scholar 

  79. Sakurada, A., Lara-Guerra, H., Liu, N., Shepherd, F. A., & Tsao, M. S. (2008). Tissue heterogeneity of EGFR mutation in lung adenocarcinoma. Journal of Thoracic Oncology, 3, 527–529.

    PubMed  Google Scholar 

  80. Nakano, H., Soda, H., Takasu, M., Tomonaga, N., Yamaguchi, H., Nakatomi, K., et al. (2008). Heterogeneity of epidermal growth factor receptor mutations within a mixed adenocarcinoma lung nodule. Lung Cancer, 60, 136–140.

    PubMed  Google Scholar 

  81. Motoi, N., Szoke, J., Riely, G. J., Seshan, V. E., Kris, M. G., Rusch, V. W., et al. (2008). Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes. EGFR mutations and gene expression analysis. American Journal of Surgical Pathology, 32, 810–827.

    PubMed  Google Scholar 

  82. Ninomiya, H., Hiramatsu, M., Inamura, K., Nomura, K., Okui, M., Miyoshi, T., et al. (2008). Correlation between morphology and EGFR mutations in lung adenocarcinomas Significance of the micropapillary pattern and the hobnail cell type. Lung Cancer, 63(2), 235–240.

    PubMed  Google Scholar 

  83. Chantranuwat, C., Sriuranpong, V., Huapai, N., Chalermchai, T., Leungtaweeboon, K., Voravud, N., et al. (2005). Histopathologic characteristics of pulmonary adenocarcinomas with and without EGFR mutation. J Med Assoc Thai, 88(Suppl 4), S322–S329.

    PubMed  Google Scholar 

  84. Ohtsuka, K., Ohnishi, H., Furuyashiki, G., Nogami, H., Koshiishi, Y., Ooide, A., et al. (2006). Clinico-pathological and biological significance of tyrosine kinase domain gene mutations and overexpression of epidermal growth factor receptor for lung adenocarcinoma. Journal of Thoracic Oncology, 1, 787–795.

    PubMed  Google Scholar 

  85. Miller, V. A., Kris, M. G., Shah, N., Patel, J., Azzoli, C., Gomez, J., et al. (2004). Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. Journal of Clinical Oncology, 22, 1103–1109.

    PubMed  CAS  Google Scholar 

  86. Blons, H., Cote, J. F., Le Corre, D., Riquet, M., Fabre-Guilevin, E., Laurent-Puig, P., et al. (2006). Epidermal growth factor receptor mutation in lung cancer are linked to bronchioloalveolar differentiation. American Journal of Surgical Pathology, 30, 1309–1315.

    PubMed  Google Scholar 

  87. Garber, M. E., Troyanskaya, O. G., Schluens, K., Petersen, S., Thaesler, Z., Pacyna-Gengelbach, M., et al. (2001). Diversity of gene expression in adenocarcinoma of the lung. Proceedings of the National Academy of Sciences of the United States of America, 98, 13784–13789.

    PubMed  CAS  Google Scholar 

  88. Bhattacharjee, A., Richards, W. G., Staunton, J., Li, C., Monti, S., Vasa, P., et al. (2001). Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proceedings of the National Academy of Sciences of the United States of America, 98, 13790–13795.

    PubMed  CAS  Google Scholar 

  89. Borczuk, A. C., Gorenstein, L., Walter, K. L., Assaad, A. A., Wang, L., & Powell, C. A. (2003). Non-small-cell lung cancer molecular signatures recapitulate lung developmental pathways. American Journal of Pathology, 163, 1949–1960.

    PubMed  CAS  Google Scholar 

  90. Tomida, S., Koshikawa, K., Yatabe, Y., Harano, T., Ogura, N., Mitsudomi, T., et al. (2004). Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients. Oncogene, 23, 5360–5370.

    PubMed  CAS  Google Scholar 

  91. Takeuchi, T., Tomida, S., Yatabe, Y., Kosaka, T., Osada, H., Yanagisawa, K., et al. (2006). Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. Journal of Clinical Oncology, 24, 1679–1688.

    PubMed  CAS  Google Scholar 

  92. Beer, D. G., Kardia, S. L., Huang, C. C., Giordano, T. J., Levin, A. M., Misek, D. E., et al. (2002). Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nature Medicine, 8, 816–824.

    PubMed  CAS  Google Scholar 

  93. Shibata, T., Hanada, S., Kokubu, A., Matsuno, Y., Asamura, H., Ohta, T., et al. (2007). Gene expression profiling of epidermal growth factor receptor/KRAS pathway activation in lung adenocarcinoma. Cancer Science, 98, 985–991.

    PubMed  CAS  Google Scholar 

  94. Hayes, D. N., Monti, S., Parmigiani, G., Gilks, C. B., Naoki, K., Bhattacharjee, A., et al. (2006). Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. Journal of Clinical Oncology, 24, 5079–5090.

    PubMed  CAS  Google Scholar 

  95. Borczuk, A. C., Kim, H. K., Yegen, H. A., Friedman, R. A., & Powell, C. A. (2005). Lung adenocarcinoma global profiling identifies type II transforming growth factor-(beta) receptor as a repressor of invasiveness. American Journal of Respiratory and Critical Care Medicine, 172, 729–737.

    PubMed  Google Scholar 

  96. Kimura, S., Hara, Y., Pineau, T., Fernandez-Salguero, P., Fox, C. H., Ward, J. M., et al. (1996). The T/ebp null mouse: thyroid-specific enhancer-binding protein is essential for the organogenesis of the thyroid, lung, ventral forebrain, and pituitary. Genes and Development, 10, 60–69.

    PubMed  CAS  Google Scholar 

  97. Yatabe, Y. (2004). Role of thyroid transcription Facotr-1 in pulmonary adenocarcinoma. In M. A. Hayat (Ed.), Handbook of immunohistochemistry and in situ hybridization of human carcinomas - molecular genetics; lung and breast carcinomas. Burlington: Elsevier Inc.

    Google Scholar 

  98. Yatabe, Y., Mitsudomi, T., & Takahashi, T. (2002). TTF-1 expression in pulmonary adenocarcinomas. American Journal of Surgical Pathology, 26, 767–773.

    PubMed  Google Scholar 

  99. Kim, C. F., Jackson, E. L., Woolfenden, A. E., Lawrence, S., Babar, I., Vogel, S., et al. (2005). Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell, 121, 823–835.

    PubMed  CAS  Google Scholar 

  100. Yatabe, Y. (2006). Molecular classification of tumors with special reference to EGFR mutation in lung cancer. Cancer Chemotherapy and Pharmacology, 58(Suppl 1), 17–23.

    Google Scholar 

  101. Breedveld, G. J., van Dongen, J. W., Danesino, C., Guala, A., Percy, A. K., Dure, L. S., et al. (2002) Mutations in TITF-1 are associated with benign hereditary chorea. Human Molecular Genetics, 11, 971–979.

    PubMed  CAS  Google Scholar 

  102. Ben-Porath, I., Thomson, M. W., Carey, V. J., Ge, R., Bell, G. W., Regev, A., et al. (2008). An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nature Genetics, 40, 499–507.

    PubMed  CAS  Google Scholar 

  103. Widschwendter, M., Fiegl, H., Egle, D., Mueller-Holzner, E., Spizzo, G., Marth, C., et al. (2007). Epigenetic stem cell signature in cancer. Nature Genetics, 39, 157–158.

    PubMed  CAS  Google Scholar 

  104. Yousem, S. A., Nikiforova, M., & Nikiforov, Y. (2008). The histopathology of BRAF-V600E-mutated lung adenocarcinoma. American Journal of Surgical Pathology, 32, 1317–1321.

    PubMed  Google Scholar 

  105. Buttitta, F., Barassi, F., Fresu, G., Felicioni, L., Chella, A., Paolizzi, D., et al. (2006). Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features. International Journal of Cancer, 119, 2586–2591.

    CAS  Google Scholar 

  106. Inamura, K., Takeuchi, K., Togashi, Y., Hatano, S., Ninomiya, H., Motoi, N., et al. (2009). EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Modern Pathology, 22, 508–515.

    PubMed  CAS  Google Scholar 

  107. Perou, C. M., Sorlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., et al. (2000). Molecular portraits of human breast tumours. Nature, 406, 747–752.

    PubMed  CAS  Google Scholar 

  108. Brenton, J. D., Carey, L. A., Ahmed, A. A., & Caldas, C. (2005). Molecular classification and molecular forecasting of breast cancer: ready for clinical application? Journal of Clinical Oncology, 23, 7350–7360.

    PubMed  CAS  Google Scholar 

  109. Iacopetta, B. (2002). Are there two sides to colorectal cancer? International Journal of Cancer, 101, 403–408.

    CAS  Google Scholar 

  110. Birkenkamp-Demtroder, K., Olesen, S. H., Sorensen, F. B., Laurberg, S., Laiho, P., Aaltonen, L. A., et al. (2005). Differential gene expression in colon cancer of the caecum versus the sigmoid and rectosigmoid. Gut, 54, 374–384.

    PubMed  CAS  Google Scholar 

  111. Shen, L., Toyota, M., Kondo, Y., Lin, E., Zhang, L., Guo, Y., et al. (2007). Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proceedings of the National Academy of Sciences of the United States of America, 104, 18654–18659.

    PubMed  CAS  Google Scholar 

  112. Sun, S., Schiller, J. H., & Gazdar, A. F. (2007). Lung cancer in never smokers—a different disease. Nature Reviews, 7, 778–790.

    PubMed  CAS  Google Scholar 

  113. Takano, T., Ohe, Y., Sakamoto, H., Tsuta, K., Matsuno, Y., Tateishi, U., et al. (2005). Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. Journal of Clinical Oncology, 23, 6829–6837.

    PubMed  CAS  Google Scholar 

  114. Varella-Garcia, M., Mitsudomi, T., Yatabe, Y., Kosaka, T., Nakajima, E., Xavier, A. C., et al. (2009). EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort. Journal of Thoracic Oncology, 4, 318–325.

    PubMed  Google Scholar 

  115. Ahn, M. J., Park, B. B., Ahn, J. S., Kim, S. W., Kim, H. T., Lee, J. S., et al. (2008). Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer? Clinical Cancer Research, 14, 3860–3866.

    PubMed  CAS  Google Scholar 

  116. Miller, V. A., Riely, G. J., Zakowski, M. F., Li, A. R., Patel, J. D., Heelan, R. T., et al. (2008). Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. Journal of Clinical Oncology, 26, 1472–1478.

    PubMed  CAS  Google Scholar 

  117. Li, A. R., Chitale, D., Riely, G. J., Pao, W., Miller, V. A., Zakowski, M. F., et al. (2008). EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. Journal of Molecular Diagnostics, 10, 242–248.

    PubMed  CAS  Google Scholar 

  118. Yokoyama, T., Kondo, M., Goto, Y., Fukui, T., Yoshioka, H., Yokoi, K., et al. (2006). EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification. Cancer Science, 97, 753–759.

    PubMed  CAS  Google Scholar 

  119. Pinter, F., Papay, J., Almasi, A., Sapi, Z., Szabo, E., Kanya, M., et al. (2008). Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry. Journal of Molecular Diagnostics, 10, 160–168.

    PubMed  CAS  Google Scholar 

  120. Sasaki, H., Shimizu, S., Okuda, K., Kawano, O., Yukiue, H., Yano, M., et al. (2009). Epidermal growth factor receptor gene amplification in surgical resected Japanese lung cancer. Lung Cancer, 64, 295–300.

    PubMed  Google Scholar 

  121. Sholl, L. M., John Iafrate, A., Chou, Y. P., Wu, M. T., Goan, Y. G., Su, L., et al. (2007). Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in nonsmall cell lung carcinoma. Modern Pathology, 20, 1028–1035.

    PubMed  CAS  Google Scholar 

  122. Sone, T., Kasahara, K., Kimura, H., Nishio, K., Mizuguchi, M., Nakatsumi, Y., et al. (2007). Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer. Cancer, 109, 1836–1844.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgment

I acknowledge the invaluable support and encouragement of Dr. Tetsuya Mitsudomi, Dr. Takashi Takahashi, and all the collaborators in our research.

Author information

Authors and Affiliations

  1. Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Kanokoden, Chikusa-ku, Nagoya, 464-8681, Japan

    Yasushi Yatabe

Authors
  1. Yasushi Yatabe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yasushi Yatabe.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yatabe, Y. EGFR mutations and the terminal respiratory unit. Cancer Metastasis Rev 29, 23–36 (2010). https://doi.org/10.1007/s10555-010-9205-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10555-010-9205-8

Keywords

Search

Navigation